gdc
Cholangiocarcinoma

Mother of 6 and a Beacon of Hope for Others

The following section features a selection of patient stories submitted to the 2015 Hero of Hope Patient Award. These stories illustrate the range of extraordinary patient profiles submitted by patients, family members, friends, and healthcare providers.
December 2015 Vol 1 No 6
Melinda Bachini
Director of Advocacy
Cholangiocarcinoma Foundation
Salt Lake City, UT

Melinda Bachini is an extraordinary person living with a rare cancer called cholangiocarcinoma (or bile duct cancer). Diagnosed in October 2009 after severe upper gastrointestinal symptoms, this wife and mother of 6 underwent a partial liver resection (surgery) and the standard chemotherapy for this cancer—Gemzar (gemcitabine) and Platinol (cisplatin).

Eventually, Platinol was stopped because of toxicity and Gemzar was continued alone, but the tumor grew again. She began treatment with Avastin (bevacizumab), but the side effects again were too severe after a few months. Because she had no good treatment options, Melinda searched for new strategies, including clinical trials. She found a clinical trial for her type of cancer, and, in March 2012, enrolled in the trial through the National Cancer Institute. Her tumor responded extremely well, and the tumor continued to shrink even after completing treatment.

I was first introduced to Melinda in a webinar she was involved in about adoptive cell therapy using tumor-infiltrating lymphocytes. This was the treatment she received at the trial, and to which her tumor responded so well. I was touched by her positive attitude in the webinar despite all that she had been through. The theme that resonated with me was her hope that other patients with cholangiocarcinoma would have successful treatment options. In February 2015, I met Melinda at the Cholangiocarcinoma Foundation Annual Conference, where she was a guest speaker. She spoke with such poise and grace to a room full of physicians, researchers, patient advocates, and volunteers, that there were few dry eyes left in the room. She discussed the side effects of chemotherapy, from which she still suffers, the scars from surgery, and the importance of seeing patients as people. She also spoke about the lack of treatment options for cholangiocarcinoma, and why this needs to change.

Melinda and I spent a short time together, where I saw what a sweet, genuine, and down-to-earth person she is. I discovered that in addition to being a wife and mother of 6, she was a paramedic. She talked about her hopes of getting back to work, because of how much she loved helping others.

I have since learned that Melinda has become a patient advocate for the Cholangiocarcinoma Foundation, and was awarded a scholarship for patient advocacy training in the 2015 Focus on Research Scholar program. She has also been featured in articles about adoptive cell therapy in the New York Times, Time, and other venues.

In addition to her full life at home in Montana and her advocacy involvement, she still finds time to serve as a moderator on the Cholangiocarcinoma Foundation patient discussion board almost daily, and speaks with other patients and their families, offering caring words, understanding, and personal experience.

Share this:

Recommended For You
Cholangiocarcinoma
Drugs for Cholangiocarcinoma (Bile Duct Cancer)
Find financial assistance programs available for cholangiocarcinoma drugs.
Genomic TestingCholangiocarcinoma
Treating Rare Cancers Can Be Hard: Why Genomic Testing Is Crucial
By Jim Palma, John Hopper
Jim Palma and John Hopper, Co-Chairs of NORD Rare Cancer Coalition, explain the difference between genetic testing and genomic profile testing, and why all patients with rare cancers should have a genomic profile done to select the best treatment for them based on potential genomic alteration.
CholangiocarcinomaFDA Approvals, News & Updates
Truseltiq Second Targeted Therapy Approved by the FDA for Patients with Advanced or Metastatic Cholangiocarcinoma and the FGFR2 Biomarker
In late May 2021, the FDA approved Truseltiq (infigratinib), a new targeted therapy, for adults with previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma and FGFR2 fusion or other rearrangement, as detected by an FDA-approved test.
Last modified: March 10, 2022

Subscribe to CONQUER: the patient voice

Receive timely cancer news & updates, patient stories, and more.


Country
Race or Ethnicity
Gender
Profession or Role
Primary Interest